A compound represented by Formula II, its enantiomers, diastereoisomers, tautomers, hydrates, solvates or a pharmaceutically acceptable salt thereof: wherein: R 6 is -CH 2 -(C 6-10)aryl or -CH 2 -heterocycle, wherein one or more hydrogen atoms of the (C 6-10)aryl group can be substituted by halogen atoms, sulfonyl(C 1-6 alkyl) groups, sulfoxide(C 1-6 alkyl) groups, sulfonamide groups, carboxylic acid groups, -C O(C 1-6 alkyl) groups, amide groups, nitro groups, cyano groups, -O(C 1-6 alkyl)groups, -SC 1-6 alkyl groups, -C 1-6 alkyl groups, -C 2-6 alkenyl groups, -C 2-6 alkynyl groups, aldehyde groups, -C (C 1-6 alkyl) groups, -NHC 1-6 alkyl groups, -N(C 1-6 alkyl) (C 1-6 alkyl) groups, amino groups, C 4-8 cycloalkyl groups or hydroxyl groups; and wherein the heterocycle group is a 3- to 10-membered ring that is monocyclic or polycyclic, aromatic or non-aromatic, saturated or unsaturated, and contains at least one heteroatom selected form O or N or S or combinations of at least two thereof interrupting the carbocyclic ring structure, wherein the heterocyclic ring can be interrupted by a C=O; the S and N heteroatoms can be oxidized, and can be substituted by halogen atoms, sulfonyl(C 1-6 alkyl) groups, sulfonamide groups, amide groups, nitro groups, cyano groups, -O(C 1-6 alkyl) groups, -S(C 1-6 alkyl) groups, -C 1-6 alkyl groups, -C 2-6 alkenyl groups, -C 2-6 alkynyl groups, amino groups, -C (C 1-6 alkyl) groups, -NH(C 1-6 alkyl) groups, -N(C 1-6 alkyl) (C 1-6 alkyl) groups, C 4-8 cycloalkyl groups or hydroxyl groups; R 7 is H, F or methyl; R 8 is Br or F; R 9 is H, F or methyl; R 10 is OH or NH 2; and including the following structures or enantiomers, diastereoisomers, tautomers, hydrates, solvates, zwitterions or a pharmaceutically acceptable salt thereof: and excluding structures or enantiomers, diastereoisomers, tautomers, hydrates, solvates, zwitterions or a pharmaceutically acceptable salt thereof: R 6 is -CH 2 -(C 6-10)aryl or -CH 2 -heterocycle, wherein one or more hydrogen atoms of the (C 6-10)aryl group can be substituted by halogen atoms, sulfonyl(C 1-6 alkyl) groups, sulfoxide(C 1-6 alkyl) groups, sulfonamide groups, carboxylic acid groups, -C O(C 1-6 alkyl) groups, amide groups, nitro groups, cyano groups, -O(C 1-6 alkyl)groups, -SC 1-6 alkyl groups, -C 1-6 alkyl groups, -C 2-6 alkenyl groups, -C 2-6 alkynyl groups, aldehyde groups, -C (C 1-6 alkyl) groups, -NHC 1-6 alkyl groups, -N(C 1-6 alkyl) (C 1-6 alkyl) groups, amino groups, C 4-8 cycloalkyl groups or hydroxyl groups; and wherein the heterocycle group is a 3- to 10-membered ring that is monocyclic or polycyclic, aromatic or non-aromatic, saturated or unsaturated, and contains at least one heteroatom selected form O or N or S or combinations of at least two thereof interrupting the carbocyclic ring structure, wherein the heterocyclic ring can be interrupted by a C=O; the S and N heteroatoms can be oxidized, and can be substituted by halogen atoms, sulfonyl(C 1-6 alkyl) groups, sulfonamide groups, amide groups, nitro groups, cyano groups, -O(C 1-6 alkyl) groups, -S(C 1-6 alkyl) groups, -C 1-6 alkyl groups, -C 2-6 alkenyl groups, -C 2-6 alkynyl groups, amino groups, -C (C 1-6 alkyl) groups, -NH(C 1-6 alkyl) groups, -N(C 1-6 alkyl) (C 1-6 alkyl) groups, C 4-8 cycloalkyl groups or hydroxyl groups; R 7 is H, F or methyl; R 8 is Br or F; R 9 is H, F or methyl; R 10 is OH or NH 2; and including the following structures or enantiomers, diastereoisomers, tautomers, hydrates, solvates, zwitterions or a pharmaceutically acceptable salt thereof: and excluding structures or enantiomers, diastereoisomers, tautomers, hydrates, solvates, zwitterions or a pharmaceutically acceptable salt thereof: R 7 is H, F or methyl; R 8 is Br or F; R 9 is H, F or methyl; R 10 is OH or NH 2; and